Etrumadenant

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma	2023/09/21	NCT06048484	Phase 2	Recruiting	Gulam Manji
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	2023/06/23	NCT05915442	Phase 2	Recruiting	Catherine Spina
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma	2023/06/02	NCT05886634	Phase 2	Active, not recruiting	Memorial Sloan Kettering Cancer Center
Study of Novel Treatment Combinations in Patients With Lung Cancer	2022/12/01	NCT05633667	Phase 2	Recruiting	Gilead Sciences
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma	2022/04/20	NCT05335941	Phase 2	Recruiting	M.D. Anderson Cancer Center
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants	2022/03/14	NCT05277012	Phase 1	Completed	Arcus Biosciences, Inc.
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer	2022/01/05	NCT05177770	Phase 2	Terminated	Coherus Biosciences, Inc.
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants	2021/12/10	NCT05154136	Phase 1	Completed	Arcus Biosciences, Inc.
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.	2021/08/27	NCT05024097	Phase 2	Recruiting	Weill Medical College of Cornell University
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers	2021/05/19	NCT04892875	Phase 1	Withdrawn	Jennifer Choe

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD

7 months ago

• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.

AI-Powered Research

Premium Access